logo-loader
HealthPharma & Biotech
GlaxoSmithKline PLC

GlaxoSmithKline to file blood cancer drug with regulators later this year

GSK bosses will use the results from this latest DREAMM-2 trial as the basis for the regulatory filings

GlaxoSmithKline PLC - GlaxoSmithKline to file blood cacner drug with regulators later this year
Multiple myeloma is the second most common blood cancer in the US

GlaxoSmithKline PLC (LON:GSK) remains on track to file its multiple myeloma drug with regulators by the end of this year after another successful late-stage clinical trial.

Multiple myeloma is a common blood cancer that is generally considered treatable but not curable. After a while, treatments tend to stop working, which is why companies are trying to come up with new drugs.

READ: GSK develops HIV treatment that only needs to be taken six times a year

In a smaller study earlier this year, called DREAMM-1, almost two-thirds of patients responded positively to the FTSE 100 drugmaker’s belantamab mafodotin proteasome inhibitor.

Data from a second, larger trial, called DREAMM-2, has now come back, which showed the drug achieved a “clinically meaningful” overall response rate in patients who had already been treated with Darzalex – an antibody developed by Belgian pharma giant Jansenn.

“I am pleased with the results of the DREAMM-2 study and excited about what these data could mean for patients with multiple myeloma who have exhausted other lines of treatment,” said chief scientific officer Hal Barron.

“We are on track to file belantamab mafodotin later this year and continue to investigate how it could help even more patients with this disease.”

Quick facts: GlaxoSmithKline PLC

Price: 1646.2 GBX

Market: LSE
Market Cap: £82.12 billion
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

'Immune activation from Clevegen has now been demonstrated' Faron Pharma CEO

Faron Pharmaceuticals Oy's (LON:FARN) Markku Jalkanen caught up with Proactive London's Andrew Scott to discuss the recently released Matins trial update which is assessing the firm's drug Clevegen. He says feedback from the dose escalation study confirmed Clevegen has good tolerability...

3 days, 15 hours ago

RNS

Director/PDMR Shareholding

4 days, 7 hours ago

Director/PDMR Shareholding

4 days, 7 hours ago

Director/PDMR Shareholding

4 days, 7 hours ago

Director/PDMR Shareholding

4 days, 7 hours ago

Director/PDMR Shareholding

1 week, 2 days ago

Director/PDMR Shareholding

1 week, 2 days ago

Director/PDMR Shareholding

1 week, 3 days ago

Director/PDMR Shareholding

2 weeks, 5 days ago

2 min read